Oryzon Genomics SA, one of the leading lights in the Spanish biotech sector, hopes that with vafidemstat, it may have a molecule that can be a 'pipeline-in-a-product' to serve as a treatment for a wide range of central nervous system (CNS) diseases.
Speaking to Scrip at the BioSpain meeting in Seville last week, Oryzon CEO Carlos Buesa said that in the past...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
